Share these talks and lectures with your colleagues
Invite colleaguesWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login
or review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Outline
- COPD definition - GOLD 2010
- Changes in COPD definition
- Lung function categories
- FEV1/FVC ratio decreases with increasing age
- Lung function in 1000 "COPD" patients
- COPD severity - U.S.
- COPD severity - England
- COPD severity - BOLD
- COPD progression (1)
- COPD progression (2)
- Natural history of chronic airflow obstruction
- What is progression of COPD?
- Diagnosed lung disease & function impairment
- Disease prevalence
- Prevalence of COPD
- Prevalence of COPD 2006 update (1)
- Prevalence of COPD 2006 update (2)
- The PLATINO and BOLD studies
- BOLD sites
- Prevalence of GOLD 2 COPD
- COPD prevalence, by sex, in U.S., 1980-2000
- Decreasing prevalence in Spain?
- No increase in Finland
- Risk of COPD among smokers
- Risk of COPD by age (10 year increase)
- GOLD 2 COPD risk factors: never smoking men
- GOLD 2 COPD risk factors: never smoking women
- Biomass fuel and COPD in China
- Early life exposures (1)
- Early life exposures (2)
- Hospitalizations
- A paradigm of exacerbations (1)
- A paradigm of exacerbations (2)
- COPD exacerbation rate
- COPD hospitalization rate
- End-of-life - disease C (1)
- COPD hospitalizations - U.S. (1980-2000)
- COPD hospitalizations - U.S. (1990-2005)
- Long-term follow-up of U.S. cohorts (1)
- Risk of death following COPD hospitalization
- Long-term follow-up of US cohorts (2)
- Risk of hospitalization
- Mortality
- End-of-life - disease C (2)
- Survival by lung function impairment
- What do COPD patients die from?
- COPD - consequences and comorbidities
- Risk of death within 5 years from baseline
- Mortality following exacerbation
- COPD deaths by sex, race; U.S., 1980 - 2000
- COPD deaths by region; U.S., 1980 - 2000
- Improving survival after COPD hospitalization
- Improving COPD mortality in U.S.
- Conclusions (1)
- Conclusions (2)
- COPD is a preventable and treatable disease
Topics Covered
- GOLD guidelines for COPD
- Lung function categories
- BOLD initiative
- Exacerbation rates for COPD patients
- Hospitalization rates for COPD patients
- Reasons for mortality in COPD patients
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Mannino, D. (2012, July 31). Epidemiology of COPD [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved March 7, 2021, from https://hstalks.com/bs/2357/.Publication History
Financial Disclosures
- Dr. David Mannino, Consultant: GlaxoSmithKline, Merck, Novartis, Nycomed, Forest; Speaker’s Bureau: Merck, GlaxoSmithKline; Grant/Research Support (Principal Investigator): GlaxoSmithKline, Forest, Boerhinger-Ingelheim.
Epidemiology of COPD
Published on July 31, 2012
30 min